Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Emerg Microbes Infect ; 12(1): 2157338, 2023 Dec.
Article in English | MEDLINE | ID: covidwho-2222491

ABSTRACT

Cytokine dynamics in patients with coronavirus disease 2019 (COVID-19) have been studied in blood but seldomly in respiratory specimens. We studied different cell markers and cytokines in fresh nasopharyngeal swab specimens for the diagnosis and for stratifying the severity of COVID-19. This was a retrospective case-control study comparing Myeloperoxidase (MPO), Adenosine deaminase (ADA), C-C motif chemokine ligand 22 (CCL22), Tumour necrosis factor alpha (TNFα) and Interleukin-6 (IL-6) mRNA expression in 490 (327 patients and 163 control) nasopharyngeal specimens from 317 (154 COVID-19 and 163 control) hospitalized patients. Of the 154 COVID-19 cases, 46 died. Both total and normalized MPO, ADA, CCL22, TNFα, and IL-6 mRNA expression levels were significantly higher in the nasopharyngeal specimens of infected patients when compared with controls, with ADA showing better performance (OR 5.703, 95% CI 3.424-9.500, p < 0.001). Receiver operating characteristics (ROC) curve showed that the cut-off value of normalized ADA mRNA level at 2.37 × 10-3 had a sensitivity of 81.8% and specificity of 83.4%. While patients with severe COVID-19 had more respiratory symptoms, and elevated lactate dehydrogenase, multivariate analysis showed that severe COVID-19 patients had lower CCL22 mRNA (OR 0.211, 95% CI 0.060-0.746, p = 0.016) in nasopharyngeal specimens, while lymphocyte count, C-reactive protein, and viral load in nasopharyngeal specimens did not correlate with disease severity. In summary, ADA appears to be a better biomarker to differentiate between infected and uninfected patients, while CCL22 has the potential in stratifying the severity of COVID-19.


Subject(s)
COVID-19 , Humans , COVID-19/diagnosis , Interleukin-6/genetics , Tumor Necrosis Factor-alpha/genetics , Retrospective Studies , Adenosine Deaminase/genetics , Adenosine Deaminase/analysis , Adenosine Deaminase/metabolism , Case-Control Studies , Peroxidase , Ligands , SARS-CoV-2/genetics , SARS-CoV-2/metabolism , Cytokines , Chemokines , Nasopharynx , Chemokine CCL22
2.
Intern Med ; 61(6): 913-916, 2022 Mar 15.
Article in English | MEDLINE | ID: covidwho-1745229

ABSTRACT

A 33-year-old woman with a fever, cough, and pharyngitis was admitted after left-sided pleural effusion was detected. The fever and upper respiratory symptoms were confirmed, and she was diagnosed with coronavirus disease (COVID-19) after showing a positive polymerase chain reaction (PCR) test. After thoracentesis, pleural fluid revealed elevated adenosine deaminase values and a positive QuantiFeron test; tuberculous pleurisy was thus suspected. Subsequent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR and anti-SARS-CoV-2 Spike IgG tests were negative, suggesting that the initial PCR result had been erroneous. However, we were unable to confirm this. Data concerning COVID-19 diagnostics are insufficient at present. It is important to make comprehensive judgments regarding the diagnosis and treatment of patients as well as public health.


Subject(s)
COVID-19 , Pleural Effusion , Tuberculosis, Pleural , Adenosine Deaminase/analysis , Adult , COVID-19/diagnosis , Comorbidity , Female , Humans , Pleural Effusion/diagnosis , SARS-CoV-2 , Tuberculosis, Pleural/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL